Abstract
Purpose
Ductal carcinoma in situ (DCIS) is a heterogeneous pre-invasive breast cancer entity in which genetic predisposition may contribute to disease development. This study evaluated the frequency and spectrum of pathogenic germline variants among Jordanian patients with DCIS who met guideline-based criteria for germline genetic testing at a single tertiary cancer centre.
Methods
We conducted a retrospective review of clinical and genetic data from patients diagnosed with DCIS. Variant classification was standardized according to American College of Medical Genetics and Genomics (ACMG) guidelines. Of 622 patients with DCIS identified during the study period, 271 (43.6%) met National Comprehensive Cancer Network (NCCN) and/or American Society of Clinical Oncology (ASCO) criteria in effect at the time of diagnosis and underwent germline genetic testing using next-generation sequencing (NGS) panels.
Results
A total of 271 patients underwent germline genetic testing. The median age at diagnosis was 47 years (range, 20–90). Pathogenic or likely pathogenic (P/LP) variants were detected in 20 patients (7.4%; 95% CI 4.6–11.2). BRCA2 was the most affected gene (n=9, 45.0%), followed by CHEK2 (n=3), and BRCA1, TP53, and ATM (n=2 each). Variants of uncertain significance (VUS) were identified in 94 patients (34.7%). Patients with P/LP variants were younger at diagnosis (mean 43.7 vs 48.9 years). P/LP variants were identified in 9.5% of patients aged ≤50 years compared with 3.9% of those aged >50 years (p=0.098, Fisher exact test). Prevalence was 7.4% among patients with a family history of cancer and 7.1% among those without (p=1.000). VUS prevalence rose with panel breadth, from 7.3% on a three-gene panel to 60.5% on an 84-gene panel.
Conclusion
In this criteria-eligible Jordanian DCIS cohort, the observed 7.4% prevalence of pathogenic germline variants supports genetic testing for patients with DCIS who meet established criteria. Carrier prevalence did not differ significantly by age at diagnosis or family history, and the study did not evaluate universal testing. The observed VUS rate was strongly dependent on panel breadth.
Keywords: breast cancer, DCIS, ductal carcinoma in-situ, germline genetic testing, BRCA
Introduction
Ductal carcinoma in situ (DCIS) is a non-invasive proliferation of malignant epithelial cells confined within the ductal basement membrane,1 and accounts for approximately 20–25% of breast cancer diagnoses in populations with established mammographic screening.2 Although not itself invasive, DCIS is an established precursor lesion and a marker of elevated risk for subsequent invasive carcinoma.3
Current NCCN 13 and ASCO–Society of Surgical Oncology guidelines 26 recommend germline genetic testing for patients with DCIS on the same basis as invasive disease, principally young age at diagnosis and family history of breast, ovarian, pancreatic, or prostate cancer. The clinical utility of a positive result differs, however. Biomarkers link molecular understanding of cancer to clinical decisions across diagnosis, risk stratification, therapy selection, and monitoring,4,5 and germline variants occupy a distinct position within that framework, being inherited rather than tumour-derived. In invasive breast cancer, BRCA1/2 status is predictive, determining eligibility for PARP inhibitor therapy in the adjuvant6 and metastatic7 settings. No such indication exists in DCIS, where the germline result functions instead as a susceptibility and risk-stratification biomarker: it informs extent of surgery and the decision between breast-conserving therapy and mastectomy, intensity of surveillance, consideration of endocrine chemoprevention, and cascade testing of at-risk relatives.8 Identifying a carrier at the in situ stage is therefore an opportunity to prevent invasive disease rather than to select systemic therapy; a distinction with particular weight in resource-limited settings, where the return on testing is measured in cancers averted.
DCIS encompasses a heterogeneous and biologically complex spectrum of neoplastic changes within the breast ductal epithelium.2,9,10 While its clinical management has historically centred on local control utilizing surgery, with or without radiation therapy, the recognition that some cases may carry a hereditary predisposition has brought increasing attention to the role of germline genetic testing (GGT) in this patient population.11–13
The development of DCIS is multifactorial, influenced by hormonal, environmental, and probably genetic factors, too. Among these, germline pathogenic variants in cancer susceptibility genes such as BRCA1, BRCA2, PALB2, CHEK2, ATM, TP53, and others have been implicated in breast cancer predisposition, with most studies historically focusing on invasive disease.14,15 Carriers of such P/LP variants are known to have substantially elevated lifetime risks of breast and ovarian cancers, which can be as high as 50–70% for breast cancer among BRCA1 or BRCA2 carriers.16–18
Current National Comprehensive Cancer Network (NCCN) guidelines recommend GGT for patients with DCIS if they fulfill certain criteria, such as diagnosis at a young age or family history of breast, ovarian, or other associated cancers.19 Nevertheless, the actual prevalence of pathogenic or likely pathogenic (P/LP) germline variants in patients with DCIS remains underexplored compared to invasive breast cancer. Reported rates vary, with some studies noting prevalence approaching 10% in selected populations, though most large-scale data derive from North American and European cohorts.20–22
Two clinical variables consistently associated with hereditary breast cancer are age at diagnosis and family history of cancer. Women diagnosed with breast malignancies at younger ages are significantly more likely to harbor P/LP germline variants.23 Similarly, a strong family history, particularly involving multiple first-degree relatives with breast or ovarian cancer, remains a hallmark of hereditary cancer predisposition syndromes.24 In DCIS, however, the strength of these associations has been less clearly defined. Clarifying the interplay between DCIS, age at diagnosis, and family history is crucial for refining testing guidelines and ensuring equitable access to GGT and counseling.
Most of the existing evidence on germline P/LP variants in DCIS comes from Western population, while data from the Middle East remain scarce. The Middle Eastern and North African (MENA) region is characterized by distinct demographic and epidemiologic patterns, including a younger age at breast cancer diagnosis compared with Western populations.25,26 In Jordan, for instance, nearly half of breast cancer patients are diagnosed before the age of 50, compared to about one-third in the United States.27,28 This younger age distribution raises the possibility of a stronger hereditary component.
Given the potential for germline P/LP variants to influence clinical management and risk reduction, understanding the P/LP variant landscape in DCIS has important implications for patients’ care. Carriers identified at the stage of DCIS can benefit from risk-reducing interventions, surveillance strategies, and cascade testing for at-risk relatives, potentially preventing invasive cancers. Conversely, a better characterization of P/LP variant prevalence in DCIS, particularly in underrepresented populations, can refine guidelines for whom to test, ensuring efficient use of limited healthcare resources.8,29
To address these knowledge gaps, we conducted a retrospective study evaluating the spectrum and frequency of P/LP variants in a large cohort of Jordanian patients with DCIS. Specifically, we examined the relationship between P/LP variant status and key clinical variables including age at diagnosis, family history of cancer, and hormonal receptor status, while also reporting on the prevalence of VUS. By comparing the findings with our previously reported results in invasive breast cancer, this study provides new insights into the role of germline predisposition in DCIS within a Middle Eastern cohort. This study addresses the prevalence and spectrum of germline variants among Jordanian patients with DCIS who met guideline-based testing criteria. It does not evaluate whether germline testing should be offered routinely to all patients with DCIS; these are distinct questions, and the present design speaks only to the former.
Methods
Study Design and Setting
This study was designed as a retrospective cohort analysis conducted at the King Hussein Cancer Center (KHCC), a tertiary referral and comprehensive cancer center in Amman, Jordan. The study period extended from July 2006 through September 2024, capturing all consecutive patients diagnosed with DCIS who were evaluated and managed at our institution during this timeframe.
The study protocol was reviewed and approved by the Institutional Review Board (IRB) at KHCC. Given the retrospective nature of the study, the requirement for informed consent was waived; however, all patient data were de-identified to ensure confidentiality in compliance with institutional and international ethical standards, including the Declaration of Helsinki.
Patient Population
Eligible patients had to have histopathological confirmed diagnosis of DCIS, with diagnosis established following surgical excision or by core needle biopsy. Eligible patients were diagnosed and managed at KHCC, with complete clinicopathologic documentation available in the institutional record, defined as documentation of age at diagnosis, family history of cancer, tumour grade, and hormone receptor status. Patients referred to KHCC solely for germline genetic testing, without accompanying clinical records, were not included. Patients must also have undergone GGT using a multigene NGS-based panel through our institutional genetic testing programme, aligned with NCCN and/or the American Society of Clinical Oncology (ASCO) guidelines in effect at the time of diagnosis. No follow-up or survival outcomes were analysed in this study. Patients with concurrent or prior diagnosis of invasive breast carcinoma or had a history of prior other malignancies were excluded.
From the total of 622 patients with DCIS identified during the study period, 271 (43.6%) underwent GGT and comprised the analytic cohort of this study. Electronic medical records were reviewed for clinical, pathologic and demographic data. Variables extracted included age at diagnosis, categorized as ≤50 years or >50 years. The cut-point of 50 years was selected because approximately half of breast cancer diagnoses in Jordan occur at or below this age, because 50 years was the NCCN age threshold for testing irrespective of family history during much of the study period, and because it permits comparison with our previous institutional analyses. Extracted variables also included family history of cancer, defined for all analyses as at least one first- or second-degree relative diagnosed with any malignancy. Hormone receptor (HR) status: estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) were determined by immunohistochemistry (IHC) according to international guidelines.30
Patients were referred to for genetic counseling and testing if they met NCCN or ASCO criteria.31 Pre-test counseling was conducted by certified genetic counselors, including education on potential implications for cancer risk management, and familial cascade testing. Post-test counseling was provided after results were available by the primary oncologist.
Germline testing at our institution is offered to patients meeting NCCN and/or ASCO criteria in effect at the time of diagnosis. Of the 622 patients with DCIS identified during the study period, 351 did not meet these criteria and were not tested; the remaining 271 met criteria and underwent testing (Supplementary Figure S1). Ascertainment among criteria-eligible patients was therefore complete, and the analytic cohort represents the criteria-eligible DCIS population at our institution rather than a selected subset of it. Clinicopathologic data were not abstracted for patients who did not undergo testing.
Relationship to previously published cohorts. Patients in this cohort were drawn from the same institutional germline testing programme that has generated several prior KHCC reports. Because patients with concurrent or prior invasive breast carcinoma were excluded by design, this cohort is disjoint from our previously published series restricted to invasive breast cancer. Partial overlap exists with reports that enrolled all guideline-eligible patients irrespective of histology, including our recent analysis of universal versus ASCO guidelines-based testing, which enrolled 1,570 consecutive newly diagnosed breast cancer patients between January 2023 and April 2024, of whom 102 had DCIS, under the same institutional approval. No DCIS-restricted analysis, gene-level distribution within DCIS, or stratified comparison by age or family history within DCIS has previously been published from this cohort, and all analyses presented here are original to this manuscript.
DNA Extraction and Sequencing
Peripheral blood samples were collected, and genomic DNA was extracted using standard commercial kits. Germline testing was performed using NGS-based multigene panels. Panels evolved over the study period but consistently included key high-penetrance genes (eg, BRCA1, BRCA2, T PALB2, PTEN, CDH1, TP53) and moderate-penetrance genes (eg, CHEK2, ATM, NBN, NF1, BARD1, RAD51C, RAD51D). Three next-generation sequencing panels were used across the study period: a BRCA1/BRCA2/PALB2 panel (n=41), a 22-gene panel (n=154), and an 84-gene panel (n=76). Copy-number and large-rearrangement analysis was performed. The distribution of results by panel is shown in Supplementary Table S1. Because BRCA1, BRCA2 and PALB2 were included on all panels while CHEK2, TP53, ATM and NF1 were included only on the 22-gene and 84-gene panels, gene-specific prevalence is reported using panel-appropriate denominators (Supplementary Table S2). Testing was performed through accredited external international reference laboratories. Sequencing achieved >99% coverage across targeted exons and flanking intronic regions. Detected variants were filtered for quality and annotated using reference databases.
Variant Classification
Variants were classified according to the American College of Medical Genetics and Genomics (ACMG) and the Association for Molecular Pathology (AMP) guidelines into pathogenic/likely pathogenic (P/LP), variants of uncertain significance (VUS), benign (B) or likely benign (LB). Variants categorized as B or LB were not included in the analytic dataset. Additionally, variants designated as “Increased Risk Alleles” (eg, specific APC polymorphisms) were reported separately. Variants were classified according to ACMG/AMP criteria. All classifications were reviewed against current variant databases as of September 2024, and the classifications reported here reflect that review rather than the classification originally assigned at the time of testing. Variant-level nomenclature for all P/LP variants is provided in Supplementary Table S3.
Statistical Analysis
Baseline demographic, clinical, and genetic characteristics were summarized using frequencies and percentages for categorical variables and medians with ranges (or means with standard deviations, where appropriate) for continuous variables.
The prevalence of P/LP variants was compared across age groups (≤50 vs >50 years) and family history categories (present vs absent) using the chi-square test or Fisher’s exact test as appropriate. Hormone receptor status was compared between carriers and non-carriers using categorical tests.
VUS were described separately, but no inferential statistical analyses were performed, given their uncertain clinical significance. Age at diagnosis was compared between carriers and non-carriers using the Mann–Whitney U-test. Categorical comparisons involving small cell counts were performed using Fisher’s exact test. Comparisons by age group and family history were exploratory, unadjusted for multiplicity, and hypothesis-generating rather than confirmatory. Patients with missing grade were excluded from the multivariable model; no imputation was performed.
Multivariable Analysis
An exploratory logistic regression model was constructed to describe associations with P/LP variant carriage rather than to establish independent predictors. Variables included were age at diagnosis (≤50 vs >50 years), family history (present vs absent), and HR status (positive vs negative). Tumour grade was not included, as the small number of carriers within grade categories could not support estimation. The model was fitted on all 271 patients. Odds ratios (OR) with 95% confidence intervals (CI) were calculated. All analyses were conducted using IBM SPSS Statistics for Windows, Version 29.0 (IBM Corp., Armonk, NY). A two-sided p-value <0.05 was considered statistically significant.
Results
Patient Characteristics
Between July 2006 and September 2024, a total of 622 patients with DCIS were treated and followed at our institution. Of these, 271 patients (43.6%) underwent GGT using NGS-based multigene panels and comprised the analytic cohort. Except for a single male patient, all enrolled patients were female. The median age at diagnosis for the entire cohort was 47 years (range, 20–90 years). Approximately one-fifth of patients (n = 49, 18.1%) were diagnosed before the age of 40, while 119 patients (43.9%) were aged 40–50 years, and 103 patients (38.0%) were older than 50 years at time of diagnosis. Family history with cancer, in at least one first- or second-degree relative, was reported by 229 patients (84.5%), among these, breast cancer was the most frequent, followed by ovarian, prostate, and gastrointestinal cancers.
Hormone receptor testing was performed in nearly all cases and majority were ER-positive (80.1%) and PR-positive (76.4%). Co-expression of ER and PR was common. Table 1 summarizes patients’ characteristics.
Table 1.
Patient Characteristics (N = 271)
| Characteristics | Number | Percentage | |
|---|---|---|---|
| Age at diagnosis (years) | Median (Range) | 47 (20–90) | |
| <40 | 49 | 18.1 | |
| 40–50 | 119 | 43.9 | |
| >50 | 103 | 38.0 | |
| Sex | Female | 270 | 99.6 |
| Male | 1 | 0.4 | |
| Estrogen Receptors (ER) | Positive | 217 | 80.1 |
| Negative | 50 | 18.5 | |
| Unknown | 4 | 1.5 | |
| Progesterone Receptors (PR) | Positive | 207 | 76.4 |
| Negative | 53 | 19.6 | |
| Unknown | 11 | 4.1 | |
| Nationality | Jordanian | 271 | 100 |
| Family History of Malignancies | Positive | 229 | 84.5 |
| Negative | 42 | 15.5 | |
| Grade | Grade-I | 36 | 13.3 |
| Grade-II | 82 | 30.3 | |
| Grade-III | 116 | 42.8 | |
| Unknown | 37 | 13.7 | |
Prevalence and Spectrum of Germline Variants
Among the 271 patients tested, 20 individuals (7.4%) were found to carry P/LP germline variants and 94 patients (34.7%) carried at least one VUS, Supplementary Table S1 and Figure 1. The most frequently mutated gene was BRCA2, detected in 9 patients (3.3% of the overall cohort, 45.0% of all carriers). Other identified P/LP variants included CHEK2 (3 patients), BRCA1 (2 patients), TP53 (2 patients), ATM (2 patients), NF1 (1 patient), and PALB2 (1 patient), Supplementary Table S2. Taken together, BRCA1 and BRCA2 accounted for 55% of all detected P/LP variants. Additionally, 4 patients (1.48%) were found to carry variants in the APC gene, classified as increased risk alleles rather than fully pathogenic variants. These were analyzed separately and were not included in the primary prevalence estimate.
Figure 1.

Results of Germline Genetic Testing (Percent).
Abbreviations: P/LP, Pathogenic/Likely pathogenic; VUS, Variant of uncertain significance.
Most VUS occurred in moderate-penetrance genes (ATM, CHEK2, NBN), though VUS were also noted in BRCA1 and BRCA2. Several patients carried multiple VUS.
Association with Age at Diagnosis and Family History
Carriers were diagnosed at a younger mean age than non-carriers (43.7 vs 48.9 years). P/LP variants were identified in 9.5% of patients aged ≤50 years (16/168) compared with 3.9% of those aged >50 years (4/103); this difference did not reach statistical significance (p=0.098, Fisher exact test; OR 2.61, 95% CI 0.85–8.02). Among patients with a family history of cancer, 7.4% (17/229) carried P/LP variants, compared with 7.1% (3/42) of those without (p=1.000; OR 1.04, 95% CI 0.29–3.73). Both comparisons were based on small numbers of carriers and are exploratory (Table 2).
Table 2.
Unadjusted and Adjusted Associations with Pathogenic or Likely Pathogenic Variant Carriage
| Variable | P/LP, n (%) | No P/LP, n (%) | Unadjusted OR (95% CI) | p | Adjusted OR (95% CI) | p |
|---|---|---|---|---|---|---|
| Age at diagnosis | ||||||
| >50 years (reference) | 4 (3.9) | 99 (96.1) | 1.00 | – | 1.00 | – |
| ≤50 years | 16 (9.5) | 152 (90.5) | 2.61 (0.85–8.02) | 0.098 | 2.61 (0.85–8.03) | 0.095 |
| Family history of cancer | ||||||
| Absent (reference) | 3 (7.1) | 39 (92.9) | 1.00 | – | 1.00 | – |
| Present | 17 (7.4) | 212 (92.6) | 1.04 (0.29–3.73) | 1.000 | 0.99 (0.28–3.63) | 0.992 |
| Hormone receptor status | ||||||
| Negative | 0 (0.0) | 39 (100.0) | Not estimable | 0.090 | Not included | – |
| Positive | 20 (8.7) | 209 (91.3) | – | – | – | – |
Notes: Unadjusted comparisons used Fisher exact tests. The multivariable model was fitted on all 271 patients with 20 events across two covariates (events per variable = 10); deviance 139.50, AIC 145.50, McFadden R2 0.023. Odds ratios represent the odds of carrying a pathogenic or likely pathogenic variant. Hormone receptor status was not included in the multivariable model: no carrier was identified among the 39 patients with receptor-negative disease, so no odds ratio was estimable. Receptor status was unknown in 3 patients, who are not shown.
Hormone Receptor Status
Hormone Receptor Status
We evaluated the distribution of receptor status among P/LP variant carriers versus non-carriers. All 20 carriers had known ER and PR status; ER status was unknown in 4 patients and PR status in 11, all within the non-carrier group, and comparisons are restricted to patients with known status. Most tumours were receptor-positive in both groups: ER positivity was 85.0% among carriers (17/20) and 81.0% among non-carriers (200/247), and PR positivity was 80.0% (16/20) and 79.6% (191/240) respectively. No statistically significant differences were observed. Tumour grade was unavailable for 37 patients (13.7%) and the number of carriers within each grade category was too small to support comparison; grade was therefore not analysed as a correlate of carrier status, and the grade distribution is reported in Table 1 as a baseline characteristic only.
Multivariable Analysis
A logistic regression model including age at diagnosis and family history was fitted on all 271 patients with 20 events, an events-per-variable ratio of 10. Younger age was associated with higher odds of carriage (adjusted OR 2.61, 95% CI 0.85–8.03; p = 0.095), while family history was not (adjusted OR 0.99, 95% CI 0.28–3.63; p = 0.992). Complete estimates are shown in Table 2. Hormone receptor status was not included: no P/LP variant was identified among the 39 patients with receptor-negative disease, compared with 20 of 229 (8.7%) with receptor-positive disease (Fisher exact p = 0.090), and the absence of P/LP in one group precluded estimation of an odds ratio.
Discussion
Ductal carcinoma in situ (DCIS) has long been recognized as a heterogeneous non-invasive entity with variable natural history and clinical significance. While it is often detected incidentally through routine mammographic screening, DCIS carries an established risk of progression to invasive breast carcinoma, mostly when left untreated.3,32 Paralleling the growing evidence in invasive breast cancer, the recent years have witnessed increasing focused research on the role of germline genetic predisposition in shaping DCIS risk and biology. Our study provides the first comprehensive evaluation of germline P/LP variant prevalence in DCIS within a Middle Eastern population, shedding light on unique P/LP variant patterns, the influence of age and family history, and the persistent challenges of variant interpretation in underrepresented cohorts.
In this cohort of 271 Jordanian patients with DCIS who underwent genetic testing, we identified P/LP germline variants in 7.4% of patients. This prevalence is noteworthy for several reasons. First, it falls within the range reported in Western cohorts, where prevalence in DCIS typically ranges from 5–10% depending on gene panel and patient selection.20–22 Direct comparison is limited, however, because our cohort was enriched by criteria-based referral and cannot be treated as an unselected DCIS population, and because the comparator cohorts differ in both ascertainment and panel breadth. In a recent study, the frequency of germline P/LP variants known to be associated with breast cancer were compared between DCIS cases, those with invasive ductal breast cancer (IDC) and unaffected controls. Cases enrolled were collected from a clinical testing cohort (n = 9,887), the UK Biobank (n = 2,421) cohort, and a population-based cohort (n= 3,876). P/LP variants were observed in 6.5% and 4.6% of women with DCIS in the clinical testing and population-based cohorts, respectively. BRCA1, BRCA2, and PALB2 P/LP frequencies were significantly lower among women with DCIS compared to those with IDC (clinical cohort: 2.8% vs 5.7%; population-based cohort: 1.7% vs 3.7%).33
In another study that included 369 women with DCIS who were participants in a large population-based case-control study of breast carcinoma in situ from the state of Connecticut, 3 (0.8%) and 9 (2.4%) patients had P/LP mutations in BRCA1 or BRCA2, respectively and one woman had a mutation in both genes. Carriers were significantly more likely than noncarriers to report a first-degree family history of breast as well as a personal history of ovarian cancer. In addition, carriers were more likely than noncarriers to be diagnosed at an early age (<50 years).34
Second, the prevalence in DCIS is lower than the 10–13% rates we previously reported in invasive breast cancer in several of our studies including a recent one that enrolled more than 6,000 Jordanian patients.35 This finding is biologically and clinically relevant. It supports the hypothesis that hereditary predisposition plays a stronger role in invasive cancers compared with in situ lesions, though DCIS remains part of the same genetic continuum. The lower rate may also reflect differences in referral patterns: patients with invasive disease are more likely to meet NCCN testing criteria than those with DCIS, potentially enriching invasive cohorts for P/LP variant carriers.
A striking feature of our findings was the predominance of BRCA2 P/LP variants, which accounted for nearly half of all identified P/LP variants. While BRCA1 and BRCA2 are both well-established contributors to hereditary breast cancer syndromes, their distribution can vary by geography and ethnicity. In Western studies of DCIS, BRCA1 P/LP variants are often encountered with similar frequency to BRCA2, especially among younger women and those with triple-negative disease. In our cohort, however, BRCA2 clearly predominated, echoing our earlier observations in invasive breast cancer within the Jordanian population.36,37 Two carriers shared the same variant, BRCA2 c.8332–3C>G, and two of the three CHEK2 carriers shared CHEK2 c.592+3A>T (Supplementary Table S3). Moreover, such enrichment may carry clinical implications, as BRCA2-associated breast cancers are more often HR-positive, aligning with the high ER/PR positivity observed in our DCIS cohort.38,39
Consistent with expectations, patients carrying P/LP variants were diagnosed with DCIS at a younger mean age (43.7 years) compared to non-carriers (48.9 years). Age at diagnosis has been repeatedly shown to be a robust predictor of P/LP variant carriage across both invasive and in situ disease. Our results align with these global observations and reinforce the importance of considering age when assessing genetic testing eligibility for DCIS patients. Interestingly, the proportion of P/LP variant carriers in women ≤50 years was more than double that in older patients (9.5% vs 3.9%). This did not reach statistical significance (p=0.08; OR 2.64, 95% CI 0.86–8.12), and the interval is consistent with no association as well as with a substantial one. The observation is concordant in direction with findings in invasive breast cancer but should be regarded as exploratory. It underscores the need to prioritize genetic counseling and testing in younger DCIS patients, particularly in regions like Jordan, where breast cancer overall presents at younger ages compared to Western populations.
Family history remains a cornerstone of hereditary cancer risk assessment. In our cohort, majority of patients (84.5%) reported a family history of cancer, reflecting the enriched nature of the tested group. P/LP carrier prevalence was almost identical in patients with and without a family history (7.4% vs 7.1%; OR 1.04, 95% CI 0.29–3.73; p=1.000). Within this cohort, family history therefore carried no discriminating information about carrier status. This is not evidence that family history is uninformative in DCIS generally: referral for testing required a qualifying family history in most cases, so 84.5% of the cohort had one and the comparison group of 42 patients was both small and atypical, having qualified for testing on other grounds. The predictive value of family history in DCIS requires evaluation in an unselected cohort. Our findings therefore support the continued use of family history as a practical and accessible tool for identifying higher-risk individuals, especially in settings where universal genetic testing is not feasible due to resource constraints.
Our analysis found no significant association between P/LP variant status and HR status, despite high rates of ER/PR positivity overall. This contrasts with invasive breast cancer, where BRCA1 P/LP variants are strongly associated with triple-negative subtype. The lack of distinction in DCIS may reflect both the small number of BRCA1 carriers in our cohort and the biology of early-stage lesions. Previous studies have reported mixed findings regarding receptor status and P/LP variant prevalence in DCIS, suggesting that HR status alone may be an unreliable predictor of hereditary predisposition in this setting.20
VUS were identified in 34.7% of patients overall, but this figure conceals a strong dependence on panel breadth (Figure 2). VUS prevalence rose from 7.3% among patients tested with a BRCA1/BRCA2/PALB2 panel, to 29.2% with a 22-gene panel, to 60.5% with an 84-gene panel. The pooled rate is therefore largely a function of the panel mix in this cohort rather than a population-specific signal, and comparisons with published rates are meaningful only between cohorts tested on panels of similar breadth. All classifications reported here were reviewed against current variant databases, so accumulated legacy classification does not contribute to the observed rate. High VUS rates carry both clinical and psychosocial consequences,40 and complicate cascade testing) (Supplementary Table S1). This emphasizes the urgent need for regional variant annotation initiatives, collaborative databases, and functional studies to reclassify variants within Middle Eastern populations. Building such resources will not only improve local clinical care but also contribute to the global effort of refining variant interpretation. Underrepresentation of Middle Eastern populations in global variant databases remains a plausible contributor to variant ambiguity in this region and continues to justify regional curation efforts. Our data do not, however, permit us to attribute the observed rate primarily to that cause.
Figure 2.

Pathogenic/Likely pathogenic (P/LP) variants (Percent).
The findings of this study have several immediate clinical implications: First, with a 7.4% prevalence of P/LP variants among criteria-eligible patients, our results support offering germline testing to patients with DCIS who meet established criteria, particularly those diagnosed at younger ages or with a family history of cancer. This aligns with ASCO and NCCN guidelines but adds evidence from a region where data were previously lacking. Second, identifying P/LP variant carriers at the DCIS stage provides opportunities for risk-reducing mastectomy, intensified surveillance, or chemoprevention, potentially preventing progression to invasive cancer. Third, positive findings allow for cascade testing of at-risk family members, enabling early detection and preventive interventions.41,42 Fourth, while universal testing may not yet be feasible in Jordan and similar contexts, our findings highlight which subgroups (younger age, family history) should be prioritized to maximize the yield of genetic testing.43,44 Importantly, the value of a positive result in DCIS differs qualitatively from that in invasive disease. Whereas BRCA1/2 status in invasive breast cancer confers eligibility for PARP inhibitor therapy, no analogous indication exists for DCIS. The yield of testing at the in situ stage is realised entirely through prevention: risk-reducing surgery, intensified surveillance, chemoprevention, and cascade testing. In a resource-limited setting, this reframing is consequential, as the return on testing in DCIS is measured in invasive cancers averted rather than treatments selected.
The clinical implications of a positive result are not uniform across genes. BRCA1, BRCA2 and PALB2 carriers are candidates for risk-reducing mastectomy and MRI surveillance, with risk-reducing salpingo-oophorectomy additionally considered in BRCA1/2. Germline TP53 carries an implication specific to the in situ setting: because radiotherapy is avoided where feasible in Li–Fraumeni syndrome, its identification may alter the choice between breast-conserving therapy and mastectomy in a patient who would otherwise receive adjuvant radiotherapy for DCIS. For the moderate-penetrance genes in our cohort (CHEK2, ATM, NF1), guidelines support enhanced surveillance but not risk-reducing mastectomy on the basis of carrier status alone. Cascade testing is appropriate across all genes, though actionability in unaffected relatives is greater for high-penetrance variants. These distinctions matter in resource-limited settings, where undifferentiated application of risk-reducing surgery would represent both overtreatment and inefficient use of surgical capacity.
Our study has several limitations. First, testing was offered on the basis of NCCN and ASCO criteria rather than universally. While ascertainment among criteria-eligible patients was complete, our estimate of 7.4% applies to this criteria-eligible population and cannot be extrapolated to unselected patients with DCIS. Second, eligibility was not a fixed standard across an 18-year period: NCCN criteria were revised repeatedly toward broader eligibility, and our programme subsequently adopted ASCO–SSO recommendations extending testing to all patients diagnosed at or below age 65. Patients were assessed against the criteria in force at their time of diagnosis, so the untested group is defined by a moving threshold and is weighted toward the earlier years of the cohort. Third, three panels of differing breadth were used. Gene-specific prevalence is reported with panel-appropriate denominators, but the pooled VUS rate reflects the panel mix rather than a population parameter, and comparisons with other cohorts are meaningful only between panels of similar breadth. Fourth, family history was self-reported and not independently verified, and because referral depended on it, the comparison group without a family history was small and atypical. Finally, with only 20 carriers, subgroup and multivariable estimates are imprecise and should be regarded as exploratory. Ethnicity was not separately recorded, so generalisation to other Arab populations requires confirmation.
Conclusion
In this criteria-eligible Jordanian cohort, P/LP germline variants were identified in 7.4% of patients with DCIS who underwent testing, with BRCA2 the most frequently affected gene. Two recurrent variants were observed, which may indicate population-specific enrichment but do not establish a founder effect without haplotype data. The high pooled VUS rate was strongly dependent on panel breadth, rising from 7.3% to 60.5% across the panels used, which should temper comparisons with cohorts tested on different platforms while leaving intact the case for regional variant curation. Carrier prevalence did not differ significantly by age at diagnosis or family history in this criteria-selected cohort. These findings support germline testing for patients with DCIS who meet established criteria, but do not address the yield or clinical utility of testing in unselected DCIS, which will require larger, preferably prospective studies using standardised contemporary panels.
Acknowledgments
The abstract of this paper was presented at the San Antonio Breast Cancer Symposium, December 2025, as a poster presentation with interim findings. The poster’s abstract was published in Clinical Cancer Research 2026;32 (4 Supplement):PS4-11-11, available at https://aacrjournals.org/clincancerres/article/32/4_Supplement/PS4-11-11/773684
Funding Statement
The authors declare that no funds, grants, or other support were received during the preparation of this manuscript.
Data Sharing Statement
The datasets generated during and analyzed during the current study are not publicly available due to data sensitivity but are available from the corresponding author on reasonable request.
Ethics Approval
This study was performed in line with the principles of the Declaration of Helsinki. Approval was granted by the Institutional Review Board (IRB) of King Hussein Cancer Center. 20 KHCC 202, 18 Mar 2020.
Informed Consent
Informed consent was obtained from all individual participants included in the study.
Consent to Publish
Not applicable. The manuscript contains no individual person’s data in any form.
Author Contributions
All authors made a significant contribution to the work reported, whether that is in the conception, study design, execution, acquisition of data, analysis and interpretation, or in all these areas; took part in drafting, revising or critically reviewing the article; gave final approval of the version to be published; have agreed on the journal to which the article has been submitted; and agree to be accountable for all aspects of the work.
Disclosure
Osama El Khatib reports Meeting/travel support from AstraZeneca, outside the submitted work. The authors declare no other financial or non-financial interests in this work.
References
- 1.Burstein HJ, Polyak K, Wong JS, Lester SC, Kaelin CM. Ductal carcinoma in situ of the breast. N Engl J Med. 2004;350:1430–12. doi: 10.1056/NEJMra031301 [DOI] [PubMed] [Google Scholar]
- 2.Tucunduva TCM, Zanetta VC, Chala LF, et al. Advancements in detection and management of ductal carcinoma in situ. Radiographics. 2025;45:e240174. doi: 10.1148/rg.240174 [DOI] [PubMed] [Google Scholar]
- 3.Wang J, Li B, Luo M, et al. Progression from ductal carcinoma in situ to invasive breast cancer: molecular features and clinical significance. Signal Transduct Target Ther. 2024;9:83. doi: 10.1038/s41392-024-01779-3 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 4.Sonkin D, Thomas A, Teicher BA. Cancer treatments: past, present, and future. Cancer Genet. 2024;286-287:18–24. doi: 10.1016/j.cancergen.2024.06.002 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 5.Liu H, Karsidag I, Golin R, Wu G. Bridging discovery and treatment: cancer biomarker. Cancers. 2025;17(22):3720. doi: 10.3390/cancers17223720 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 6.Tutt ANJ, Garber JE, Kaufman B, et al. Adjuvant olaparib for patients with BRCA1- or BRCA2-mutated breast cancer. N Engl J Med. 2021;384:2394–2405. doi: 10.1056/NEJMoa2105215 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 7.Robson M, Im SA, Senkus E, et al. Olaparib for metastatic breast cancer in patients with a germline BRCA mutation. N Engl J Med. 2017;377:523–533. doi: 10.1056/NEJMoa1706450 [DOI] [PubMed] [Google Scholar]
- 8.Domchek SM, Friebel TM, Singer CF, et al. Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality. Jama. 2010;304:967–975. doi: 10.1001/jama.2010.1237 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 9.Riggi JAM, Kassem I, Galant C, et al. Predictive histopathological markers for upstaging to invasive carcinoma after a biopsy diagnosis of ductal carcinoma in situ of the breast: a hypothesis-generating systematic review. Pathobiology. 2025;93:34–47. doi: 10.1159/000547335 [DOI] [PubMed] [Google Scholar]
- 10.Zhou W, Jirström K, Johansson C, et al. Long-term survival of women with basal-like ductal carcinoma in situ of the breast: a population-based cohort study. BMC Cancer. 2010;10:653. doi: 10.1186/1471-2407-10-653 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 11.Bijker N, Donker M, Wesseling J, den Heeten GJ, Rutgers EJ. Is DCIS breast cancer, and how do I treat it? Curr Treat Options Oncol. 2013;14:75–87. doi: 10.1007/s11864-012-0217-1 [DOI] [PubMed] [Google Scholar]
- 12.Salvatorelli L, Puzzo L, Vecchio GM, et al. Ductal carcinoma in situ of the breast: an update with emphasis on radiological and morphological features as predictive prognostic factors. Cancers. 2020;12:609. doi: 10.3390/cancers12030609 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 13.Nicosia L, Bozzini AC, Penco S, et al. A model to predict upstaging to invasive carcinoma in patients preoperatively diagnosed with low-grade ductal carcinoma in situ of the breast. Cancers. 2022;14:370. doi: 10.3390/cancers14020370 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 14.Yang RL, Mick R, Lee K, et al. DCIS in BRCA1 and BRCA2 mutation carriers: prevalence, phenotype, and expression of oncodrivers C-MET and HER3. J Transl Med. 2015;13:335. doi: 10.1186/s12967-015-0698-3 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 15.Mbemi A, Khanna S, Njiki S, Yedjou CG, Tchounwou PB. Impact of gene-environment interactions on cancer development. Int J Environ Res Public Health. 2020;17:8089. doi: 10.3390/ijerph17218089 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 16.Mavaddat N, Peock S, Frost D, et al. Cancer risks for BRCA1 and BRCA2 mutation carriers: results from prospective analysis of EMBRACE. J Natl Cancer Inst. 2013;105:812–822. doi: 10.1093/jnci/djt095 [DOI] [PubMed] [Google Scholar]
- 17.Kuchenbaecker KB, Hopper JL, Barnes DR, et al. Risks of breast, ovarian, and contralateral breast cancer for BRCA1 and BRCA2 mutation carriers. Jama. 2017;317:2402–2416. doi: 10.1001/jama.2017.7112 [DOI] [PubMed] [Google Scholar]
- 18.Antoniou A, Pharoah PD, Narod S, et al. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet. 2003;72:1117–1130. doi: 10.1086/375033 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 19.National Comprehensive Cancer Network. Genetic/familial high-risk assessment: breast, ovarian, pancreatic and prostate. Version 2.2026. Available from: https://www.nccn.org/professionals/physician_gls/pdf/genetics_bopp.pdf. Accessed April 2, 2026. [DOI] [PubMed]
- 20.Petridis C, Arora I, Shah V, et al. Frequency of pathogenic germline variants in BRCA1, BRCA2, PALB2, CHEK2 and TP53 in ductal carcinoma in situ diagnosed in women under the age of 50 years. Breast Cancer Res. 2019;21:58. doi: 10.1186/s13058-019-1143-y [DOI] [PMC free article] [PubMed] [Google Scholar]
- 21.Feszak S, Feszak IJ, Kluźniak W, et al. BRCA1 and BRCA2 mutations in Polish women with ductal carcinoma in situ. Cancers. 2025;17:613. doi: 10.3390/cancers17040613 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 22.Feszak S, Kluźniak W, Feszak I, et al. Association analysis of germline mutations in CHEK2, PALB2, NBN and RECQL with the risk of ductal carcinoma in situ in Polish women. Hered Cancer Clin Pract. 2025;23:19. doi: 10.1186/s13053-025-00320-z [DOI] [PMC free article] [PubMed] [Google Scholar]
- 23.de Sanjosé S, Léoné M, Bérez V, et al. Prevalence of BRCA1 and BRCA2 germline mutations in young breast cancer patients: a population-based study. Int J Cancer. 2003;106:588–593. doi: 10.1002/ijc.11271 [DOI] [PubMed] [Google Scholar]
- 24.Loman N, Johannsson O, Kristoffersson U, Olsson H, Borg A. Family history of breast and ovarian cancers and BRCA1 and BRCA2 mutations in a population-based series of early-onset breast cancer. J Natl Cancer Inst. 2001;93:1215–1223. doi: 10.1093/jnci/93.16.1215 [DOI] [PubMed] [Google Scholar]
- 25.Abdel-Razeq H, Rayyan Y, Al-Rabi K, et al. Transforming cancer care in Jordan: a 10-year comprehensive patient-centred strategy guided by local experts. Lancet Oncol. 2025;26:e352–e359. doi: 10.1016/S1470-2045(25)00129-9 [DOI] [PubMed] [Google Scholar]
- 26.El Saghir NS, Khalil MK, Eid T, et al. Trends in epidemiology and management of breast cancer in developing Arab countries: a literature and registry analysis. Int J Surg. 2007;5:225–233. doi: 10.1016/j.ijsu.2006.06.015 [DOI] [PubMed] [Google Scholar]
- 27.Abdel-Razeq H, Al-Ibraheem A, Al-Rabi K, Shamiah O, Al-Husaini M, Mansour A. Cancer care in resource-limited countries: Jordan as an example. JCO Glob Oncol. 2024;10:e2400237. doi: 10.1200/GO.24.00237 [DOI] [PubMed] [Google Scholar]
- 28.Abdel-Razeq H, Mansour A. Challenges and opportunities in breast cancer care in low-resourced countries, Jordan as an example. Cancers. 2024;16:1751. doi: 10.3390/cancers16091751 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 29.Salhab M, Bismohun S, Mokbel K. Risk-reducing strategies for women carrying BRCA1/2 mutations with a focus on prophylactic surgery. BMC Womens Health. 2010;10:28. doi: 10.1186/1472-6874-10-28 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 30.American Society of Clinical Oncology/College of American Pathologists. Guideline recommendations for human epidermal growth factor receptor HER2 testing in breast cancer. J Oncol Pract. 2007;3:48–50. doi: 10.1200/JOP.0718501 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 31.Bedrosian I, Somerfield MR, Achatz MI, et al. Germline testing in patients with breast cancer: ASCO-Society of Surgical Oncology guideline. J Clin Oncol. 2024;42:584–604. doi: 10.1200/JCO.23.02225 [DOI] [PubMed] [Google Scholar]
- 32.Hulahan TS, Angel PM. From ductal carcinoma in situ to invasive breast cancer: the prognostic value of the extracellular microenvironment. J Exp Clin Cancer Res. 2024;43:329. doi: 10.1186/s13046-024-03236-z [DOI] [PMC free article] [PubMed] [Google Scholar]
- 33.Huang H, Couch RE, Karam R, et al. Pathogenic variants in cancer susceptibility genes predispose to ductal carcinoma in situ of the breast. Clin Cancer Res. 2025;31:130–138. doi: 10.1158/1078-0432.CCR-24-1884 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 34.Claus EB, Petruzella S, Matloff E, Carter D. Prevalence of BRCA1 and BRCA2 mutations in women diagnosed with ductal carcinoma in situ. Jama. 2005;293:964–969. doi: 10.1001/jama.293.8.964 [DOI] [PubMed] [Google Scholar]
- 35.Abdel-Razeq H, Tamimi F, Bani Hani H, et al. The evolution of breast cancer genetic testing: comparative outcomes of NCCN, ASCO, and universal guidelines in 6,000+ patients. J Clin Oncol. 2025;43(16 suppl):10619. doi: 10.1200/JCO.2025.43.16_suppl.10619 [DOI] [Google Scholar]
- 36.Abdel-Razeq H, Tamimi F, Iweir S, et al. Genetic counseling and genetic testing for pathogenic germline mutations among high-risk patients previously diagnosed with breast cancer: a traceback approach. Sci Rep. 2024;14:12820. doi: 10.1038/s41598-024-63300-8 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 37.Abdel-Razeq H, Abujamous L, Abunasser M, Edaily S, Bater R. Prevalence and predictors of germline BRCA1 and BRCA2 mutations among young patients with breast cancer in Jordan. Sci Rep. 2021;11:14906. doi: 10.1038/s41598-021-94403-1 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 38.Metcalfe K, Lynch HT, Foulkes WD, et al. Oestrogen receptor status and survival in women with BRCA2-associated breast cancer. Br J Cancer. 2019;120:398–403. doi: 10.1038/s41416-019-0376-y [DOI] [PMC free article] [PubMed] [Google Scholar]
- 39.Bane AL, Beck JC, Bleiweiss I, et al. BRCA2 mutation-associated breast cancers exhibit a distinguishing phenotype based on morphology and molecular profiles from tissue microarrays. Am J Surg Pathol. 2007;31:121–128. doi: 10.1097/01.pas.0000213351.49767.0f [DOI] [PubMed] [Google Scholar]
- 40.Welsh JL, Hoskin TL, Day CN, et al. Clinical decision-making in patients with variant of uncertain significance in BRCA1 or BRCA2 genes. Ann Surg Oncol. 2017;24:3067–3072. doi: 10.1245/s10434-017-5959-3 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 41.Abdel-Razeq H, Mustafa R, Abdel-Razeq S, et al. Pathogenic germline variants in patients with breast cancer: conversations across generations, practices and patients’ attitude. Front Genet. 2023;14:1194075. doi: 10.3389/fgene.2023.1194075 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 42.Nicoara D, Pop IC, Muntean MV, Ilies RA, Achimas-Cadariu PA. Primary prevention through prophylactic mastectomy and breast reconstruction: an exploratory study on patient satisfaction and quality of life. J Clin Med. 2025;14:8093. doi: 10.3390/jcm14228093 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 43.Samaddar NJ, Riegert-Johnson D, Boardman L, et al. Comparison of universal genetic testing vs guideline-directed targeted testing for patients with hereditary cancer syndrome. JAMA Oncol. 2021;7:230–237. doi: 10.1001/jamaoncol.2020.6252 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 44.Abdel-Razeq H, Rayyan Y, Al-rabi K. Jordan: a 10-year comprehensive patient-centred strategy guided by local experts. Lancet Oncol. 2025;26:e352–e359. doi: 10.1016/S1470-2045(25)00129-9 [DOI] [PubMed] [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.
Data Availability Statement
The datasets generated during and analyzed during the current study are not publicly available due to data sensitivity but are available from the corresponding author on reasonable request.
